Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael S Vincent

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
JID Innovations : Skin Science From Molecules to Population Health|October 24, 2022
Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a TrialBrett King, Emma Guttman-Yassky, Elena Peeva, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|August 30, 2024
Exploratory pharmacodynamics and efficacy of PF-06817024 in a Phase 1 study of patients with chronic rhinosinusitis and atopic dermatitisSpencer I Danto, Nikolaos Tsamandouras, Padma Reddy, et al.
JAMA Dermatology|December 20, 2023
Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical TrialLawrence F Eichenfield, Sanela Tarabar, Seth Forman, et al.
JAMA Dermatology|October 3, 2019
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical TrialMelinda J Gooderham, Seth B Forman, Robert Bissonnette, et al.
The Journal of Investigative Dermatology|April 21, 2020
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled TrialSeth B Forman, David M Pariser, Yves Poulin, et al.
British Journal of Clinical Pharmacology|June 3, 2026
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-07261271 in healthy participantsSrividya Neelakantan, Christopher Banfield, Kenneth Hung, et al.
Arthritis Research & Therapy|August 2, 2011
A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the kneeStanley B Cohen, Susanna Proudman, Alan J Kivitz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 14, 2025
Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to MethotrexateSpencer I Danto, Mikhail Salganik, Anindita Banerjee, et al.
The British Journal of Dermatology|March 27, 2023
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group studyMegan N Landis, Stacy R Smith, Gabriel Berstein, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 17, 2021
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-AnalysesNan Bing, Huanyu Zhou, Xing Chen, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
JID Innovations : Skin Science From Molecules to Population Health|October 24, 2022
Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a TrialBrett King, Emma Guttman-Yassky, Elena Peeva, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|August 30, 2024
Exploratory pharmacodynamics and efficacy of PF-06817024 in a Phase 1 study of patients with chronic rhinosinusitis and atopic dermatitisSpencer I Danto, Nikolaos Tsamandouras, Padma Reddy, et al.
JAMA Dermatology|December 20, 2023
Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical TrialLawrence F Eichenfield, Sanela Tarabar, Seth Forman, et al.
JAMA Dermatology|October 3, 2019
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical TrialMelinda J Gooderham, Seth B Forman, Robert Bissonnette, et al.
The Journal of Investigative Dermatology|April 21, 2020
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled TrialSeth B Forman, David M Pariser, Yves Poulin, et al.
British Journal of Clinical Pharmacology|June 3, 2026
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-07261271 in healthy participantsSrividya Neelakantan, Christopher Banfield, Kenneth Hung, et al.
Arthritis Research & Therapy|August 2, 2011
A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the kneeStanley B Cohen, Susanna Proudman, Alan J Kivitz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 14, 2025
Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to MethotrexateSpencer I Danto, Mikhail Salganik, Anindita Banerjee, et al.
The British Journal of Dermatology|March 27, 2023
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group studyMegan N Landis, Stacy R Smith, Gabriel Berstein, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 17, 2021
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-AnalysesNan Bing, Huanyu Zhou, Xing Chen, et al.
Pageof 4